NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
OTC · BIOE · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Bio Essence Corporation’s quoted price sits in the upper half of its reported 52-week range, 14.89% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Bio Essence Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Bio Essence Corporation is a global enterprise specializing in herbal health, dietary, and nutritional solutions. It supplies healthcare professionals with a diverse range of herbal remedies, offered in various forms such as granules, capsules, pills, and tablets. Furthermore, the company extends custom formulation and original equipment manufacturing (OEM) services to these practitioners and manufactures and distributes its own line of health supplements. Founded in 2000, Bio Essence Corporation maintains its corporate headquarters in Irvine, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:27 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$275.20+$4.16 (+1.53%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
CA$0.02-CA$0.01 (-25.0%)
Revive Therapeutics Ltd.’s quoted price sits in the lower half of its reported 52-week range, 81.25% below the high.
$0.00$0.00 (0.0%)
Ubiquitech Software Corp.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.02-$0.01 (-20.0%)
Rafarma Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.49% below the high.
$0.00+$0.00 (+50.0%)
LiveWire Ergogenics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.57% below the high.
CA$0.01CA$0.00 (0.0%)
Pharmadrug Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.0% below the high.
$0.00$0.00 (0.0%)
Resilient Healthcare Corp’s quoted price sits in the lower half of its reported 52-week range, 92.98% below the high.
